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ABSTRACT

ARTICLE HISTORY

The blood-brain and blood-tumor barriers represent highly specialized structures responsible for tight
regulation of molecular transit into the central nervous system. Under normal circumstances, the relative impermeability of the blood-brain barrier (BBB) protects the brain from circulating toxins and contributes to a brain microenvironment necessary for optimal neuronal function. However, in the context
of tumors and other diseases of central nervous system, the BBB and the more recently appreciated
blood-tumor barrier (BTB) represent barriers that prevent effective drug delivery. Overcoming both
barriers to optimize treatment of central nervous system diseases remains the subject of intense scientific investigation. Although many newer technologies have been developed to overcome these barriers, thermal therapy, which dates back to the 1890 s, has been known to disrupt the BBB since at
least the early 1980s. Recently, as a result of several technological advances, laser interstitial thermal
therapy (LITT), a method of delivering targeted thermal therapy, has gained widespread use as a surgical technique to ablate brain tumors. In addition, accumulating evidence indicates that laser ablation
may also increase local BBB/BTB permeability after treatment. We herein review the structure and
function of the BBB and BTB and the impact of thermal injury, including LITT, on barrier function.
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Introduction
The blood-brain and blood tumor barriers (BBB and BTB)
regulate not only the composition of the central nervous system (CNS) microenvironment but also the entry of potentially
therapeutic drugs. These barriers render targeted delivery of
drugs to the CNS more challenging than delivery to other
organs. The restrictive nature of the BBB has contributed to
the therapeutic failures in glioblastoma (GBM), the most
common malignant primary brain tumor [1]. GBM carries a
median survival of approximately 15 months and a five-year
survival of less than 10% [2]. Although many drugs capable
of killing these cancer cells in vitro have been developed,
only temozolomide has been found to be effective when
administered systemically in vivo. Furthermore, angiogenesis
in glioblastoma leads to the formation of abnormal tumor
microvessels and the creation of the BTB, which has only limited and heterogeneous permeability and introduces additional complexity in drug delivery to tumor tissue [3]. Thus,
understanding and overcoming the BBB and BTB to treat
CNS diseases such as GBM remain active areas of
investigation.
Several strategies to enhance delivery of therapeutic compounds to brain tumors, such as direct delivery to the tissue,
use of carrier molecules, and local physical disruption of the
BBB have been developed [4–9]. In particular, local disruption
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of the BBB and BTB has the dual benefit of increasing permeability to otherwise brain-impermeant drugs and mitigating
the impact of these drugs on normal parenchyma.
Thermal therapy as a treatment for a variety of conditions
has been explored for over a century. The development of
microwave and laser probes drove the evolution of thermal
therapy from whole-body hyperthermia to the creation of
focal thermal lesions. Laser interstitial thermal therapy (LITT)
has become a frequently used treatment for CNS lesions in
the past decade, with recent evidence suggesting that LITT
may create local disruption of the BBB and BTB [10]. LITT is a
stereotactic, minimally invasive, cytoreductive technique that
can be used to create targeted and conformal thermal injury
to treat a wide array of CNS lesions [11–13]. The technique
was first described in 1983 but only recently gained traction,
primarily due to technological advances, such as MRI thermometry and improved laser probe design [14,15]. On postprocedural MRI scans, increased contrast enhancement can
be observed at the edge of the LITT treatment area
(Figure 1). This and other imaging markers of increased BBB
permeability support the hypothesis that LITT disrupts the
BBB and BTB [10].
In this review we first describe the biology and physiology
of the BBB and BTB. We then highlight the challenges these
barriers create for treatment of CNS diseases, particularly
brain tumors. Lastly, we briefly describe LITT, the effect that
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Figure 1. Pre- and post-operative MRI from a patient treated with laster interstital thermal therapy. A patient with glioblastoma underwent left-sided LITT. (A)
Preoperative T1 MRI with contrast shows a rim-enhancing lesion with central hypointensity. (B) MRI performed 1 day after LITT shows the characteristic targetoid
appearance of a lesion treated with LITT, with an area of central enhancement surrounded by a hyperintense rim. White arrowhead points to the area of central
contrast-enhancement that was not present prior to treatment. (C) MRI performed 2 months later shows resolution of the central enhancement seen post
operatively.

thermal therapy has on the BBB and BTB, and the implications for the treatment of CNS disease.

The blood-brain and blood-tumor barriers
Blood brain barrier physiology
Neural signaling requires a unique and finely controlled biochemical environment. Cellular associations at the BBB maintain homeostasis through passive selective permeability,
active molecular and cellular transport, and regulation of
local cerebral blood flow. The functional unit of the BBB is
comprised of specialized endothelial cells, astrocytes, pericytes, microglia, and neurons and is known as the neurovascular unit [16]. Evolutionary conservation of the function of
the BBB has allowed research of the BBB in invertebrates and
non-human vertebrates to translate into human studies.
Examples of conserved components include endothelial cells,
pericytes, and perivascular glial cells [17].
The vascular capillary lumen is separated from the CNS by
a single layer of specialized endothelial cells connected to
each other by tight junctions and adherens junctions. Tight
junctions, comprised of occludin, junctional adhesion molecules (JAMs), and claudins 3 and 5, among others, are a hallmark of the BBB and contribute to the significant reduction
in permeability of macromolecules and polar solutes from
the plasma in the capillary lumen into brain parenchyma
through paracellular diffusion. Occludin and claudins interact
with ZO-1, ZO-2, ZO-3, and cingulin, proteins involved with
regulation of intracellular architecture. Adherens junctions
are comprised of cadherin proteins that provide an intercellular link between cytoplasmic alpha, beta, and gamma catenin, and are essential for providing structural support to
tight junction complexes. The tight junctional complex maintains a precisely controlled microenvironment by significantly
limiting the diffusion of solutes and small molecules [16].

Junctional properties are dynamic and can be influenced by
local circulating and CNS factors [18]. The barrier function of
the BBB is significantly altered by not only the expression of
tight junctional proteins but also their organization [19].
Adjacent to the endothelial layer is a basement membrane composed of a 30–40 nm thick lamina consisting of
type IV collagen, laminin, and fibronectin, which intimately
interact with pericytes and the end-foot processes of astrocytes [20]. Pericytes are cells that reside at intervals along
capillary walls and play a role in controlling capillary diameter through intracellular actin fibers, which is important for
regulating metabolic supply in response to neuronal activity
[21]. Recent research suggests that the classic definition of
pericytes can be subdivided into subtypes that serve unique
roles depending on the organ in which they are located and
their location along the capillary bed. For example, single
cell sequencing data from mice suggests that lung and brain
pericytes are unique cell populations, and pericytes near the
arteriole end of the capillary bed are involved in regulating
cerebral blood flow while those in the middle of the capillary
bed are more important for maintaining the blood-brain barrier [22,23]. They are also critical for the development of the
BBB during embryogenesis, and the disruption of pericyteendothelial cell interactions may lead to BBB dysfunction in
the setting of CNS disease [24]. Astrocytes interact with
endothelial cells and pericytes via end-feet processes to
modulate the expression and polarization of tight junction
proteins and secrete factors that support the function of
neighboring cells. Astrocytes also play a role in modulating
cerebral blood flow to match glucose and oxygen supply
with neuronal demand [25].
Passive diffusion of molecules into the CNS is primarily
determined by lipid solubility, which allows movement
through the lipid bilayer of the endothelial cells that comprise the BBB [26]. Dissolved gases such as oxygen and carbon dioxide move down their concentration gradients and
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do not require active transport. Paracellular diffusion limits
the movement of even small molecules essential to CNS
function, such as glucose and amino acids, and therefore,
BBB solute carriers (SLCs) expressed in the endothelial cell
membrane are necessary for their transport into the CNS.
Notable examples include GLUT1 for glucose transport and
LAT1 for large neutral amino acid transport. SLCs and tight
junctions work together to establish and maintain molecular
gradients across the BBB. In contrast, large molecules are
transported across the BBB by endocytosis, which allows solutes such as peptides to enter the CNS. This mechanism may
be unique to the endothelial cells of the BBB, as transcytosis
here routes molecules away from the degradative lysosomal
pathway, unlike in in peripheral tissues, which typically
involves the lysosomal degradation pathway [27].
Active transport across the BBB occurs via ATP-binding
cassette (ABC) transporters. ABC transporters are a superfamily of proteins that are ATP-driven, membrane-bound transporters located on the luminal surface that transport small
molecules back into circulation, and include P-glycoprotein
(P-gp) and multidrug resistance-associated proteins (MRPs)
[28,29]. Members of this superfamily of proteins have been
implicated in the development of the multidrug resistance
(MDR) phenotype. For example, MRP1 has been found in several CNS tumors including oligodendrogliomas, anaplastic
astrocytomas, and GBM, and its degree of expression has
been associated with higher grade gliomas [28,30]. Indeed,
there is evidence that chemotherapeutics may induce MRP1
expression and contribute to resistance [31]. Thus the efficacy of therapeutic agents may also be influenced by potential efflux in addition to entry mechanisms.
The CNS is thought to be an ‘immune-privileged’ site, but
mechanisms for cellular entry into the CNS do exist. For
example, during embryogenesis and in pathologic conditions,
cells from the peripheral circulation derived from the monocyte lineage enter the brain via the BBB and differentiate into
microglia. Furthermore, in the setting of an intact BBB, subsets of T and B cells have been observed to enter the CNS via
diapedesis through endothelial cells limited to CSF spaces
including the ventricular system and subarachnoid space,
which in turn drain to deep cervical lymph nodes [32,33].
Interstitial fluid, distinct from CSF, drains from the CNS parenchyma along basement membranes in the walls of cerebral
capillaries Moreover, dural lymphatics have been recently
shown to drain CSF into deep cervical lymph nodes are separated from the CNS parenchyma by the glia limitans and the
arachnoid blood-CSF barrier [33]. Lastly, in the setting of
pathological conditions such as infection, tight junctions may
be opened and circulating macrophages and mononuclear
leukocytes enter the CNS via transcellular or paracellular
mechanisms [34]. Dendritic cells have also been shown to
migrate out of the CNS to peripheral tissues to activate T cells
and initiate an immune response against CNS antigens [35].

Blood-tumor barrier physiology
BBB dysfunction is a hallmark of most high-grade gliomas
and intracranial metastases and is best illustrated by the
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appearance of these tumors on various conventional MR
sequences. For example, extravasation of gadolinium, a
hydrophilic contrast agent, on T1-weighted sequences is a
marker of the physical disruption of the BBB and is seen in
virtually all cases of high-grade glioma and metastatic CNS
disease. In addition, beyond the contrast-enhancing portion,
there is often a T2-hyperintense region indicating abnormal
accumulation of fluid or vasogenic edema. These areas notably allow diffusion of fluid without the accumulation of
gadolinium as seen in more central regions of the tumor.
Positron emission tomography imaging of tracers such as
11
C-methionine, 18F-fluoro-ethyl tyrosine, and 3,4-dihydroxy6-18F-fluoro-l-phenylalanine have shown active transport of
these molecules across the BBB and accumulate inside the
tumor tissue. These studies suggest that there are varying
degrees of BTB/BBB disruption in the setting of brain
tumors [36,37].
A well-known characteristic of GBM is angiogenesis and
neovascularization via a vascular endothelial growth factor
(VEGF)-mediated mechanism that produces the immature,
dilated, and leaky blood vessels of the blood-tumor barrier
(BTB). In a mouse model of glioma, glioma cells displace the
astrocyte end-feet from the endothelial surface, which in
turn disrupts tight junctions and allows extravasation of various molecules from circulating blood into brain parenchyma
[38]. Consistently, downregulation of critical BBB tight junction proteins such as claudin-1 and -5 has been found in
human glioblastoma [39]. Aquaporins are membrane transport proteins that mediate water transport and play a key
role in maintaining BBB integrity. Aquaporin-4 overexpression
in astrocytes is believed to be a compensatory result of the
loss of end-feet and increase in the volume of the perivascular space [40]. Moreover, as glioma cells infiltrate, they hijack
the autoregulatory function of native astrocytes and independently mediate vascular tone [38]. The unique microenvironment created by the BTB, that of low oxygen tension
and high interstitial pressure, is thought to contribute to
selection of tumor cells with a more malignant phenotype [41].
BTB permeability is a dynamic phenomenon that evolves
throughout the process of tumorigenesis, proliferation, and
infiltration. The neurovascular unit exhibits different properties in different regions of the tumor. The BTB is more permeable in the tumor core compared to the tumor periphery,
and a nearly impermeable BBB can be seen in the surrounding normal parenchyma [42]. Concordantly, imaging studies
have demonstrated heterogeneous permeability to small and
large molecules, and heterogeneous perfusion as seen on
dynamic susceptibility contrast (DSC)-MRI [43]. Anti-cancer
agents have been described to have varying degrees of distribution across the normal BBB and BTB [36]. Heterogeneous
permeability of the BTB may be secondary to alterations in
cell types that normally make up the neurovascular unit [44].
In a model of metastatic breast cancer, increased expression
of a subpopulation of pericytes was associated with
increased local BTB permeability, suggesting that atypical cellular heterogeneity contributes to heterogeneous BBB/BTB
permeability in these lesions [45].
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BTB permeability also varies between tumor types.
Medulloblastoma, a childhood brain tumor, has vastly different prognosis depending on subtype. Phoenix et al. demonstrated that WNT-medulloblastoma, a curable form of
medulloblastoma, exhibits paracrine signals mediated by
mutant beta-catenin, which produces fenestrated endothelial
cells that allows the intracellular accumulation of chemotherapeutics [46]. In contrast, SHH-medulloblastoma, a more
treatment-resistant subtype, exhibits a less permeable BTB,
which is thought to play a role in its resistance to chemotherapy [46]. These results suggest that BTB permeability is a
heterogeneous phenomenon that impacts drug delivery, and
therefore efficacy of treatment, to target tissues.

Circumventing the BBB and BTB
Under normal circumstances, the biochemical and mechanical properties of the BBB and BTB prevent the penetration
of many therapeutic agents into the CNS [42]. Although
brain tumors can alter and even increase permeability of the
BBB, these BTB effects are heterogeneous, and in any case,
treating the region of near normal BBB permeability in the
tumor periphery remains challenging [47]. These regions can
be visualized on T1-weighted MRI as those that do not
exhibit gadolinium enhancement but may be hyperintense
on T2-weighted sequences [48]. Attempts to overcome the
challenges of drug delivery to CNS tumors range from development of new drugs or drug combinations to mechanical
disruption of the BBB and BTB.
Many pharmacologic agents are susceptible to multidrug
resistance ABC transporters that actively efflux drugs out of
the brain. Unfortunately, attempts to develop an effective
drug efflux transporter blocker have failed in clinical trials
[49]. Osmotic blood-brain barrier disruption has also been
attempted to circumvent the BBB and the BTB. In early
experiments, Rapoport et al. injected intra-arterial mannitol
to draw free water away from the endothelial cells and thus
create an opening of the tight junctions for several hours
during which chemotherapeutics could be administered [4,
50]. More recent studies have investigated the use of

mannitol to enhance delivery of stem cells and their growth
factors across the BBB as well as combining mannitol to
temozolomide to increase BBB permeability [51,52].
Unfortunately, the clinical benefit of utilizing chemotherapeutics in this manner has not been clearly established, and
this method has been associated with toxicity, such as permanent hearing loss, which is thought to be due to the nonselective entry of inflammatory markers and resulting
neurotoxicity as well as the unclear time course of BBB permeability in relation to mannitol administration [53].
Besides chemical means to temporarily disrupt the BBB,
ultrasound has also been used to mediate BBB permeability
to enhance drug delivery and remains an active area of
research. Focused ultrasound (FUS) with circulating microbubbles is able to noninvasively and transiently open the
BBB in a controllable manner [54,55]. Low amplitude FUS
causes repetitive expansion and contraction of microbubbles
to induce shear stress on cells and eventually create pores
through cell membranes [56]. High amplitude FUS can create
shockwaves and microjets, which may temporarily disrupt
tight junctions, increase permeability, and enhance drug
delivery [57]. Preliminary results from a phase I/II clinical trial
(NCT02253212) utilizing an implanted ultrasound device on
patients with recurrent GBM show that this technique produces transient BBB disruption for the administration of carboplatin [58]. At present, although a number of clinical trials
are underway, few clinical applications for FUS have been
developed in comparison to LITT (Table 1).
More recently, bone marrow and X-linked non-receptor
tyrosine kinase (BMX) inhibitor ibrutinib has been shown to
target glioblastoma cell-derived pericytes—and not normal
pericytes—to increase BTB permeability and chemotherapeutic efficacy [44]. Thus, combining ibrutinib with traditionally
brain-impermeant chemotherapeutics may represent a novel
means of tumor-targeted drug delivery. Various other methods to improve drug penetration across the BBB have also
been developed, such as receptor-mediated transcytosis
(RMT) and adsorptive-mediated transcytosis (AMT). Although
RMT has been a widely researched method, historically, its
efficacy is limited by ligand competition and receptor

Table 1. Comparison of focused ultrasound (FUS) and laser interstitial thermal therapy (LITT).
FUS [59]
Mechanism for target ablation
Mechanism for opening BBB
Simultaneous use of MRI thermometry
Invasiveness
Precision
Current usage in lesion ablation
Primary brain neoplasm
Metastatic disease
Radiation necrosis
Epilepsy
Essential tremor
Parkinson’s disease
Major depressive disorder
Obsessive compulsive disorder
Trigeminal neuralgia
Current usage in BBB modulation
Brain tumor and chemotherapy enhancement
Alzheimer’s disease

HIFU to raise temperature through acoustic energy
HIFU/LIFU þ microbubbles to temporarily disrupt
endothelial tight junction
Yes
Noninvasive, can be performed with mild sedation
<1 mm
Phase I
Phase I

LITT
Laser to raise temperature through heat energy
Unknown
Yes
Invasive, must be performed under general
anesthesia
1.5 mm ± 0.7 mm

I
II
I
I
I
I

Clinical
Clinical
Clinical
Clinical
Clinical
None
None
None
None

Phase I and II
Phase I and II

Phase I
None

Phase
Phase
Phase
Phase
Phase
Phase

use
use
use
use
use
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saturation. In contrast, AMT is not hindered by these limiting
factors. In one form of AMT, molecules can be conjugated to
cell-penetrating peptides, small (<30 amino acid) peptides
that are capable of crossing the BBB without significant
membrane damage. For example, Angiopep (a 19-amino acid
peptide) conjugated particles are based on modification with
a ligand of the low density lipoprotein receptor related protein 1 (LRP1). These agents take advantage of the ability of
LRP1 to mediate endocytosis of amyloid-beta peptides across
the BBB [8]. This technique has been utilized to facilitate
delivery of doxorubicin in a mouse model of glioma, which
was associated with improved median survival and low toxicity [9]. In a study of mice implanted with breast tumor xenografts, intra-arterially administered Angiopep-2 conjugated
to an anti-HER2 mAb was associated with an increased survival. Importantly, 60% of the administered dose was localized to the brain [60].
Neurosurgical approaches have also been utilized to
bypass the BBB and BTB. These include intracavitary drug
injection through implanted devices such as the Ommaya
reservoir and direct local delivery, such as Gliadel
wafers [5,6].

Thermal therapy
The concept of treating malignancy with hyperthermia predates modern medicine, fueled by early anecdotal reports of
tumor regression after systemic fever or infection from nineteenth century physicians. Preliminary studies on the use of
hyperthermia as early as the 1890s relied on administration
of pyrogenic toxins to elevate whole body temperature [61].
Unfortunately these and other methods that rely on whole
body hyperthermia are limited as temperature elevation
remains modest, well below the critical 43  C thermal death
threshold for neoplastic cells, to prevent injury to normal tissue. Nonetheless, attempts to utilize whole body hyperthermia continued well into the twentieth century. Importantly,
this led to the discovery of the synergistic impact of hyperthermia on BBB-impermeant chemotherapeutic agents, leading to the hypothesis that hyperthermia may disrupt the BBB
[62]. Unfortunately potentiation of chemotherapeutics in the
setting of whole body hyperthermia was not localized to the
CNS, resulting in increased toxicity to normal organs and
tissue.
To overcome the limitations of whole-body hyperthermia,
the use of targeted hyperthermia for treatment of glioblastoma was explored by Salcmann and Samaras in the early
1980s. In their pioneering work, human subjects with glioblastoma were implanted with a flexible wire microwave
radiator that was connected transcutaneously to a 2450 MHz
microwave generator to deliver heat up to a temperature of
45  C to the tumor [63,64]. Although they were able to safely
deliver treatments, the impact on survival was modest at
best. Also, at the time, specifically delivering thermal therapy
to tumor tissue without injuring the surrounding parenchyma was not technologically possible.
In 1983 Bown described LITT in brain tumor models using
a neodymium:yttrium-aluminum-garnet (Nd:YAG) laser as
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another means of creating targeted thermal lesions [14,
65–67]. Unfortunately, the technique was limited by inadequate cooling of the laser probe and the inability to accurately measure brain temperature to guide ablation.
The modern LITT procedure relies on several technologies
that have since been developed to overcome these challenges. In the United States, two LITT systems are available:
the NeuroBlateV System (Monteris Medical, Winnipeg,
Manitoba, Canada) and the VisualaseV Thermal Therapy
System (Visualase Inc., Houston, Texas, USA). Although the
two systems have several technical differences, the underlying biological principles are similar [11,68–70].
R

R

Litt
Energy from photons emitted by lasers applied intracranially
has a variety of effects depending on the way in which it is
applied. For example, using two-photon laser techniques,
lesions as small as 15 mm have been created in the parenchyma to study the microglial response to intracranial injury
and in the wall of CNS microvasculature to study hemorrhagic and ischemic stroke [71,72]. LITT is a clinical application of laser energy to create thermal lesions as large as
3 cm through conduction of heat to tissues distant from the
laser probe. LITT is widely utilized in neuro-oncology due to
its ability to effectively kill tumor cells. Photons emitted by
the laser are absorbed by tumor cell chromophores, resulting
in chromophore excitation followed by release of thermal
energy and heating of surrounding tissue [65,73]. In order to
achieve cell death, a minimum temperature must be maintained for a certain duration of time. Although heat capacity
may vary between cell types and target organs, a specific
thermal dose results in cellular necrosis and tissue coagulation. Thermal treatment of tumors takes advantage of the
fact that tumor cells are more sensitive to thermal injury
than normal cells. However, this therapeutic window is narrow, and accurate targeting and temperature measurement
is therefore critical. In the case of CNS tumors, antineoplastic
effects become apparent at 42  C, while normal neurons
become damaged at 43  C [74].
A LITT procedure is performed in conjunction with intraoperative MRI. Once the patient is placed under general anesthesia and intubated, the head is fixed in a rigid skull clamp
and registered to a frameless stereotactic navigation system
to plan the burr hole and trajectory of the laser probe. A
skin incision and bur hole are made, after which the laser
probe is inserted using stereotactic navigation. The patient’s
head is then placed within the MRI bore with the probe in
place (Figure 2(A)). An MRI scan is performed, allowing for
monitoring of the position of the probe, which can be
advanced or withdrawn during the procedure. Additionally,
firing of the laser probe is interleaved with acquisition of MR
images in real time. This information is integrated by a computer connected to the MRI scanner, allowing for measurement of tissue temperature using MR thermometry (Figure
2(B)). Using this technique, tissue temperature can be measured to within 1  C with a spatial resolution of 1–2 mm
[15,65]. Importantly, this allows for measurement of
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Figure 2. Cranial laser interstitial thermal therapy. (A) Schematic depiction of the NeuroBlateV LITT delivery system (Monteris Medical, Winnipeg, Manitoba,
Canada). The laser probe is stereotactically inserted through an approximately 0.5 cm skin incision and bur hole in the skull. The patient is then placed in the MRI
scanner and the laser is activated remotely, with pulses interleaved with MRI acquisition for temperature monitoring. (B) Computer interface of the NeuroBlateV
LITT delivery system (Monteris Medical, Winnipeg, Manitoba, Canada). MRI scans acquired while the probe is firing are overlaid in the computer interface with thermal damage threshold lines (blue TDT line shown here represents 43  C for 10 min). As shown here, intraoperative MRI sequences can also be merged with previously acquired diffusion tensor MR imaging to highlight critical white matter tracts such as the corticospinal tract.
R

R

temperatures distant from the laser probe, allowing for ablation of the target lesion while sparing normal tissue. Using
the Arrhenius equation, which predicts cell death as a function of tissue temperature and ablation time, the computer
is able to display zones of tissue damage to ensure adequate
ablation of the target lesion [65,70,75].
Although LITT is less invasive than open craniotomy and
tumor debulking, it is not without risk. Reported complications of LITT include arterial injury, seizures, transient or permanent neurologic deficit, cerebrospinal fluid leak, and
infection [76,77]. In a recent series of 102 patients treated
with MR-guided LITT, 13.7% (n ¼ 14) developed new deficits,
64.3% (n ¼ 9) of which had complete resolution within
1 month post-op, 7.1% (n ¼ 1) had partial resolution of symptoms, 14.3% (n ¼ 2) did not have resolution of symptoms at

the most recent follow-up, and 14.3% (n ¼ 2) died without
resolution of symptoms [78]. Strategies to mitigate complications include the use of trajectories that avoid eloquent
structures, staged procedures for larger lesions, and the use
of steroids to reduce post-operative edema.

Impact of LITT on the blood-brain and blood-tumor
barriers
Beyond tissue ablation, little is known about the biological
impact of LITT on a cellular or molecular level in the CNS.
Early work investigating the impact of diffuse thermal injury
provides some insight into the biological impact of LITT on
the BBB. In a rabbit model, hyperthermia to 42.5  C was
found to increase permeability to Trypan blue [79].
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Subsequently, in a rat model, Oscar et al. found increased
permeability to inulin and D-mannitol, which are normally
brain-impermeant, for up to 4 h after microwave hyperthermic therapy [80]. In rats, whole head hyperthermia creates
acute lesions in regions of the brain more susceptible to
hyperthermia. Using this model, Urakawa et al. studied the
structure of acute thermal lesions with electron microscopy.
Like the thermal injury pattern produced by LITT, the authors
identified 3 concentric regions of thermal lesions: a necrotic
center, a surrounding reactive zone and a rim of viable brain
tissue. In both the reactive zone and viable rim, pial and cortical vessels were permeable to intravenous horse radish peroxidase, a BBB tracer, and astrocyte end-feet were observed
to be swollen. Importantly, increased BBB permeability was
observed up to 3 days after treatment, indicating thermal
therapy may create a therapeutic window of time for delivery of adjuvant therapies [81].
More recently, Leuthardt et al. found elevated serum levels of brain specific enolase, which is normally restricted to
the CNS, after laser ablation in patients with recurrent glioblastoma, suggesting that CNS permeability is indeed
increased by LITT. Importantly, peak permeability appears to
occur 1–2 weeks after ablation and resolves by 4–6 weeks.
Additionally, post-LITT MRI findings suggest that the region
of increased permeability includes a rim of parenchyma surrounding the treated lesion [10]. Thus LITT may create a window of time during which drugs may be administered to
treat residual, surrounding infiltrative disease. The release of
proteins normally confined to the CNS, such as brain specific
enolase, into the systemic circulation after LITT may also
have implications for the immune response after laser ablation that remain to be investigated.
Our data from a LITT mouse model also suggests that
laser ablation transiently increases BBB/BTB permeability,
with peak permeability occurring within 1 week and lasting
up to 30 days after ablation. Importantly, molecules as large
as human IgG (approximately 150 kDa) are able to enter the
CNS after LITT. At the cellular level, increased permeability
appears to be mediated by increased transcytosis and/or
tight junction disruption. In vivo, LITT increased the brain
permeability of intravenous doxorubicin, and LITT in combination with doxorubicin was associated with improved survival
when compared to either treatment alone [82]. Related to
this finding, we have two ongoing clinical trials investigating
the use of the combination of LITT and doxorubicin in adult
and pediatric populations (NCT01851733 and NCT02372409,
respectively).

phenomenon are just beginning to be understood. Future
directions may include investigating the relationship
between thermal dosage and the spatiotemporal relationship
of the diffusion of molecules various sizes across the BBB/
BTB. Further understanding in this area could lead to
enhancing the sensitivity and specificity of LITT on target tissue of interest to maximize efficacy and minimize
complications.

Conclusion
The BBB and BTB are comprised primarily of pericytes, endothelial cells and astrocyte end-feet which combine to form a
restrictive barrier to the CNS. Techniques to overcome the
BBB and BTB, which prevent the effective delivery of drugs
to the CNS, are an area of intense investigation. Laser ablation is a thermal therapy technique that may increase BBB
and BTB permeability in a targeted fashion, opening the possibility of combination therapies that may more effectively
treat CNS tumors.
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